Premium
Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma
Author(s) -
McKelvey Eugene M.,
Gottlieb Jeffrey A.,
Wilson Henry E.,
Haut Arthur,
Talley Robert W.,
Stephens Ronald,
Lane Montague,
Gamble Jess F.,
Jones Stephen E.,
Grozea Petre N.,
Gutterman Jordon,
Coltman Charles,
Moon Thomas E.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i
Subject(s) - vincristine , medicine , prednisone , chop , cyclophosphamide , lymphoma , gastroenterology , chemotherapy , rituximab , combination chemotherapy , surgery , oncology
Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vin‐cristine, and prednisone) and HOP (Adriamycin, vincristine, and prednisone) was used as treatment for patients with pathologically staged, advanced non‐Hodgkin's lymphoma. Among 204 evaluable patients treated on CHOP there were 71% complete remissions with 92% overall responses. Among the 216 evaluable patients on HOP there were 61% complete remissions and 88% responses. Complete remission rates among patients with histiocytic lymphoma were comparable to those of patients with lymphocytic disease. Patients with nodular lymphoma had higher rates of complete remission than their counterparts with diffuse lymphoma. This was noted with both CHOP (78% vs. 67%) and HOP (67% vs. 60%) induction therapy. Rapid responses were common, as more than 14% of complete remissions and 66% of overall responses were achieved with the first course of treatment. Patients in complete remission have been maintained with either cyclophosphamide, vincristine, and prednisone (COP) or arabinosyl cytosine, vincristine, and prednisone (OAP). After 1 year, 86% of patients on COP and 80% on OAP are projected to be free of disease.